Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder

BackgroundThe cost of schizophrenia in Japan is high and new long-acting injectable (LAI) antipsychotics might be able to reduce costs by causing a reduction of hospital stays. We aim to estimate budget effects of the introduction of a new 1-month LAI, paliperidone palmitate, in Japan.MethodsA budget impact analysis was conducted from a payer perspective. The model took direct costs of illness into account (ie, costs for inpatient and outpatient services, as well as drug costs). The robustness of the model was checked using a sensitivity analysis.ResultsAccording to our calculations, direct total costs of schizophrenia reach 710,500 million yen a year (US$6 billion). These costs decrease to 691,000 million yen (US$5.9 billion) 3 years after the introduction of paliperidone palmitate.ConclusionFrom a payer point of view, the introduction of a new treatment for schizophrenia in Japan helps to save resources and is not associated with a higher financial burden.

show abstract

“… 9 – 16 Accordingly, several cost-effectiveness studies demonstrated economic superiority of LAIs over oral antipsychotics. 17 – 24 …”

Section: Introductionmentioning

confidence: 99%

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan

Mahlich

Nishi²,

Saito³

2015

CEOR

View full text Add to dashboard Cite

show abstract

“… 10 Using an economic model based on the clinical trial event rates observed in the long-term PP1M versus placebo relapse-prevention study, it was estimated that total mean annual medical costs were $7140 lower for patients with schizoaffective disorder who are treated with PP1M versus placebo. 10 , 20 The reductions in annual medical costs in patients treated with PP1M versus placebo were largely attributed to reduced risk of relapse. There are no other randomized clinical trials that have specifically evaluated the efficacy and safety of other APs for the treatment of schizoaffective disorder.…”

Section: Discussionmentioning

confidence: 99%

Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States

Joshi¹,

Lin²,

Lingohr-Smith³

et al. 2016

J Clin Psychopharmacol

View full text Add to dashboard Cite

This study assessed real-world treatment patterns and antipsychotic (AP) medication adherence among commercially insured US patients with schizoaffective disorder (SCA). Continuously insured adults aged 18 years or older with a diagnosis of SCA from January 1, 2009, to December 31, 2012, were identified from the Clinformatics Data Mart database. Patients were categorized into 2 cohorts: incident or prevalent SCA. Demographics and clinical characteristics were evaluated during the baseline period. Use of psychiatric medications and adherence to AP medications were evaluated during a 12-month follow-up period after index diagnosis of SCA. Of the overall study population (N = 2713; mean age, 40.2 y; 52.7% female), 1961 patients (72.3%) (mean age, 38.7 y; 51.3% female) had incident SCA, and 752 patients (27.7%) (mean age, 43.9 y; 56.5% female) had prevalent SCA. Antipsychotics were used by 74.8% of patients in the overall study population during the follow-up period. The most commonly prescribed oral AP was risperidone (23.9%), followed by quetiapine (21.4%) and aripiprazole (20.4%). Use of any long-acting injectable APs in the overall study population during the follow-up period was less than 3%. A total of 49.0% and 38.0% of the overall study population had medication possession ratios and proportion of days covered for APs of 80% or greater, respectively. Overall use of long-acting injectable APs for the treatment of SCA is low, and adherence to AP medications, measured by both medication possession ratio and proportion of days covered, is suboptimal among patients with SCA in the real-world setting.

show abstract

Maintenance treatment with antipsychotic drugs for schizophrenia

Ceraso

Lin

Schneider‐Thoma

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder

Abstract: Use of PP1M for treatment of patients with schizoaffective disorder was associated with a significantly lower rate of relapse and a reduction in medical costs compared to placebo. Further evaluation in the real-world setting is warranted.

Cited by 6 publications

References 16 publications

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan

Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States

Maintenance treatment with antipsychotic drugs for schizophrenia

Contact Info

Product

Resources

About